Antiulcerant Drugs market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antiulcerant Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2032.
Segment by Type
- Proton Pump Inhibitors
- H2 Receptor Antagonists
- Gastric Mucosal Protective Drugs
- Antibiotics
- Antacids
- Prostaglandin Agonists
Segment by Application
- Mouth Ulcers
- Stomach Ulcers
- Leg Ulcer
- Esophageal Ulcer
- Bleeding Ulcer
- Neuropathic Ulcers
- Venous Stasis Ulcers
- Arterial (Ischemic) Ulcers
- Others
By Region
- North America
- United States
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Nordic Countries
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
By Company
- Takeda Pharmaceutical
- Eisai
- Daewoong Pharmaceutical
- Allergan
- AstraZeneca plc
- Valeant
- Zydus
- Shire
